Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIUMPH Trial
2013-000173-77Phase 2Terminated
- Sponsor
- Institut Jules Bordet
- Start
- Aug 2013
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of doxorubicin and paclitaxel in breast cancer, sponsored by Institut Jules Bordet. Primary endpoints: Ovarian function recovery at 12 months after end of chemotherapy and Ovarian reserve at 12 months after end of chemotherapy. Started Aug 2013; status: terminated.
02
Drugs
doxorubicinpaclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2013-000173-77.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000173-77.